NASDAQ:SGMT

Sagimet Biosciences Q2 2025 Earnings Results & Report

Sagimet Biosciences logo
$9.85 -0.28 (-2.76%)
Closing price 04:00 PM Eastern
Extended Trading
$9.88 +0.04 (+0.36%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sagimet Biosciences beat analyst earnings expectations in its Q2 2025 results, released August 13, 2025. The company reported EPS of -$0.32 versus the -$0.52 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Sagimet Biosciences EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.52
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Sagimet Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sagimet Biosciences Q2 2025 Earnings FAQ

Sagimet Biosciences (NASDAQ:SGMT) reported earnings of -$0.32 per share for Q2 2025, beating the consensus estimate of -$0.52. The report was announced on Wednesday, August 13, 2025.

Sagimet Biosciences Earnings Headlines

HC Wainwright Expects Lower Earnings for Sagimet Biosciences
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Sagimet Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sagimet Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sagimet Biosciences and other key companies, straight to your email.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ:SGMT) is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body’s production of fatty acids. The company is based in San Mateo, California.

Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions.

Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne. Its work focuses on advancing these candidates through clinical development rather than marketing approved medicines.

View Sagimet Biosciences Profile